BackgroundCheck.run
Search For

John J Lewicki, 41Albuquerque, NM

Known as:
John Joseph Lewicki John L Lewicki John Jones Jones John Lewick John L Gaskins
Related to:
Julia Mae Blue 70

John Lewicki Phones & Addresses

Albuquerque, NM   

Hanahan, SC   

El Cerrito, CA   

Phoenix, AZ   

1329 Condon St, Charlotte, NC 28216   

416 Yuma St, Charlotte, NC 28213    704-5979643   

Riviera Beach, FL   

416 Yuma St, Charlotte, NC 28213   

Get Report
Control this profile

Mentions for John J Lewicki

Career records & work history

Medicine Doctors

John D. Lewicki

Specialties:
Otolaryngology
Work:
Group Health Olympia Medical Center
700 Lilly Rd NE, Olympia, WA 98506
360-9237000 (phone) 360-9237099 (fax)
Languages:
English
Description:
Mr. Lewicki works in Olympia, WA and specializes in Otolaryngology. Mr. Lewicki is affiliated with Providence Centralia Hospital and Providence St Peter Hospital.

John Lewicki resumes & CV records

Resumes

John Lewicki Photo 27

Dishwasher Cook

Location:
Albuquerque, NM
Industry:
Architecture & Planning
Work:
Cheese Cake Factory
Dishwasher Cook
John Lewicki Photo 28

John Lewicki

John Lewicki Photo 29

John Lewicki

Publications & IP owners

Wikipedia

John Lewicki Photo 32

A Certain Sacrifice

A Certain Sacrifice is the singer Madonna's first movie, made in September 1979, written and directed by Stephen Jon Lewicki. Madonna starred with Jeremy

Us Patents

Compositions And Methods For Inhibiting Wnt-Dependent Solid Tumor Cell Growth

US Patent:
7723477, May 25, 2010
Filed:
Oct 31, 2006
Appl. No.:
11/589931
Inventors:
Austin Gurney - San Francisco CA, US
John Lewicki - Los Gatos CA, US
Sanjeev Satyal - San Carlos CA, US
Timothy Hoey - Hillsborough CA, US
Assignee:
OncoMed Pharmaceuticals, Inc. - Redwood City CA
International Classification:
A61K 38/00
C07K 1/00
C07K 14/00
C07K 17/00
C07K 2/00
C07K 4/00
C07K 5/00
C07K 7/00
C07K 16/00
US Classification:
530350, 530300, 514 12
Abstract:
The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.

Antibodies To Notch Receptors

US Patent:
8226943, Jul 24, 2012
Filed:
Jul 8, 2009
Appl. No.:
12/499627
Inventors:
Austin L. Gurney - San Francisco CA, US
Timothy Charles Hoey - Hillsborough CA, US
Edward Thein Htun van der Horst - Palo Alto CA, US
Aaron Ken Sato - Burlingame CA, US
Yuan Ching Liu - Fremont CA, US
Maureen Fitch Bruhns - San Mateo CA, US
John A. Lewicki - Los Gatos CA, US
Assignee:
OncoMed Pharmaceuticals, Inc. - Redwood City CA
International Classification:
A61K 39/395
C07K 16/28
C07K 14/705
C12N 5/00
US Classification:
4241301, 4241331, 4241411, 4241431, 435326, 435331, 435334, 530350, 5303871, 5303881, 53038815, 53038822
Abstract:
The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.

Nucleic Acid Molecules Encoding Soluble Frizzled (Fzd) Receptors

US Patent:
8324361, Dec 4, 2012
Filed:
Mar 15, 2010
Appl. No.:
12/724169
Inventors:
Austin Gurney - San Francisco CA, US
John Lewicki - Los Gatos CA, US
Sanjeev Satyal - San Carlos CA, US
Timothy Hoey - Hillsborough CA, US
Assignee:
OncoMed Pharmaceuticals, Inc. - Redwood City CA
International Classification:
C07H 21/04
C12P 21/06
C12N 1/20
C12N 15/00
C12N 5/00
C12N 5/02
C12N 15/74
US Classification:
536 235, 435 691, 4352523, 4353201, 435325, 435471, 536 2353
Abstract:
The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.

Methods Of Treatment By Administering Antibodies To Notch Receptors

US Patent:
8425903, Apr 23, 2013
Filed:
May 15, 2012
Appl. No.:
13/472305
Inventors:
Austin L. Gurney - San Francisco CA, US
Timothy Charles Hoey - Hillsborough CA, US
Edward Thein Htun van der Horst - Palo Alto CA, US
Aaron Ken Sato - Burlingame CA, US
Yuan Ching Liu - Fremont CA, US
Maureen Fitch Bruhns - San Mateo CA, US
John A. Lewicki - Los Gatos CA, US
Assignee:
OncoMed Pharmaceuticals, Inc. - Redwood City CA
International Classification:
A61K 39/395
A61P 35/00
C07K 16/28
US Classification:
4241301, 4241331, 4241381, 4241411, 4241421, 4241431, 514 133, 514 192, 514 193, 514 194, 5303871, 5303873, 5303877, 5303881, 53038815, 53038822
Abstract:
The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.

Compositions And Methods For Diagnosing And Treating Cancer

US Patent:
2007011, May 24, 2007
Filed:
Oct 31, 2006
Appl. No.:
11/589993
Inventors:
Austin Gurney - San Francisco CA, US
John Lewicki - Los Gatos CA, US
Sanjeev Satyal - San Carlos CA, US
Timothy Hoey - Hillsborough CA, US
International Classification:
A61K 39/395
C07K 16/30
C12N 5/06
US Classification:
424143100, 424155100, 424178100, 530388220, 530391100, 435326000, 435336000, 435338000
Abstract:
An isolated antibody that specifically binds to an extracellular domain of two or more human FZD receptors and inhibits growth of tumor cells is described. Also described is a method of treating cancer comprising administering an antibody of the present disclosure in an amount effective to inhibit tumor cell growth.

Notch Binding Agents And Antagonists And Methods Of Use Thereof

US Patent:
2013026, Oct 3, 2013
Filed:
Mar 1, 2013
Appl. No.:
13/782671
Inventors:
Timothy Charles Hoey - Hillsborough CA, US
Edward Thein Htun van der Horst - Palo Alto CA, US
Aaron Ken Sato - Burlingame CA, US
Yuan Ching Liu - Fremont CA, US
Maureen Fitch Bruhns - San Mateo CA, US
John A. Lewicki - Los Gatos CA, US
Assignee:
OncoMed Pharmaceuticals, Inc. - Redwood City CA
International Classification:
C07K 16/28
US Classification:
435331, 536 2353, 4353201, 43525233, 43525231, 4352542
Abstract:
The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.

Notch Binding Agents And Antagonists And Methods Of Use Thereof

US Patent:
2013029, Nov 7, 2013
Filed:
Mar 14, 2013
Appl. No.:
13/826432
Inventors:
Timothy Charles Hoey - Hillsborough CA, US
Edward Thein Htun van der Horst - Palo Alto CA, US
Aaron Ken Sato - Burlingame CA, US
Yuan Ching Liu - Fremont CA, US
Maureen Fitch Bruhns - San Mateo CA, US
John A. Lewicki - Los Gatos CA, US
International Classification:
C07K 16/22
US Classification:
5303873, 5303879
Abstract:
The present invention relates to Notch-binding agents and Notch antagonists and methods of using the agents and/or antagonists for treating diseases such as cancer. The present invention provides antibodies that specifically bind to a non-ligand binding region of the extracellular domain of one or more human Notch receptor, such as Notch2 and/or Notch3, and inhibit tumor growth. The present invention further provides methods of treating cancer, the methods comprising administering a therapeutically effective amount of an antibody that specifically binds to a non-ligand binding region of the extracellular domain of a human Notch receptor protein and inhibits tumor growth.

Methods For Treating Cancer With Dll4 Antagonists

US Patent:
2013032, Dec 5, 2013
Filed:
Nov 15, 2011
Appl. No.:
13/885249
Inventors:
Robert Joseph Stagg - Moraga CA, US
Steven Eugene Benner - Seattle WA, US
John Lewicki - Los Gatos CA, US
Timothy Charles Hoey - Hillsborough CA, US
Assignee:
OncoMed Pharmaceuticals, Inc. - Redwood City CA
International Classification:
A61K 39/395
A61K 45/06
US Classification:
4241721
Abstract:
The present invention provides methods for treating cancer. More particularly, the invention provides methods for treating cancer comprising administrating doses of a DLL4 antagonist.

Amazon

John Lewicki Photo 33

Organizational Justice: The Search For Fairness In The Workplace (Issues In Organization And Management Series)

Author:
Blair H. Sheppard, Roy J. Lewicki, John W. Minton
Publisher:
Macmillan Pub Co
Binding:
Hardcover
Pages:
227
ISBN #:
0669158453
EAN Code:
9780669158458
Some managers conduct inconsistant performance reviews, pay inequitable salaries, and dismiss employees arbitrarily. Concerns about justice are pervasive in the workplace: they arise whenever rules are made, interpreted, or applied to organizational activities and practices. In this analysis, the au...

Possible Relatives

Daniel J Lewicki  Aaron R Lewicki  Edna Lewicki  Elizabeth W Lewicki  Gregory W Lewicki  James S Lewicki  Jason Lewicki  John M Johnson  John Stamps  John R Stan 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.